Due to its rarity, the exact incidence is unknown ... About 40 to 50 years ago, the 10-year survival rate for PNH was only around 50%. However, over the past 15 years, advancements in treatment ...

(RTTNews) - Omeros Corp. (OMER), Friday announced that it has initiated clinical trial site activation for its Phase 3 program evaluating zaltenibart or OMS906 in paroxysmal nocturnal ...

Advances in treatments have significantly improved survival rates, highlighting the importance of recognizing symptoms and seeking medical advice promptly. PNH can develop at any age, from early ...